Clinical Trial

A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

Study acronym: STARPAC2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multi-centre, randomised, stratified, phase IIb clinical trial of ATRA administered in combination with gemcitabine and nab-paclitaxel in patients with laPDAC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-01-24; most recent amendment 2026-01-05.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-06-03
Trial Details
NCT Number NCT04241276
Lead Sponsor Queen Mary University of London
Collaborators: Medical Research Council, Celgene
Conditions Pancreatic Cancer
Enrollment 170 participants
Start Date 2020-04-30
Primary Completion 2028-06-29 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-07